1 The e ects of ozone inhalation (90 min, 2.15+0.05 p.p.m.) and their modiÂźcation by dexamethasone (20 mg kg 71 ) or the phosphodiesterase-4 inhibitor, rolipram (1 mg kg 71 ), administered (i.p.) 24 and 0.5 h before and 24 h after ozone exposure were examined in conscious guineapigs. 2 Ozone caused an early-phase bronchoconstriction (EPB) as a fall in speciÂźc airways conductance (sG aw ) measured by whole body plethysmography, followed at 5 h by a late-phase bronchoconstriction (LPB) and increased respiratory rate. Rolipram did not alter this proÂźle but dexamethasone inhibited the EPB. 3 Airway hyperreactivity to inhaled histamine (1 mM, 20 s) occurred at 0.5, 2, 12, 24 and 48 h after ozone inhalation, the 2 h change being abolished by rolipram and dexamethasone. 4 Bronchoalveolar lavageÂŻuid (BALF) macrophages, eosinophils and neutrophils were signiÂźcantly (P50.05) elevated at 12, 24 and 48 h after ozone exposure, the 48 h inÂŻux being signiÂźcantly attenuated (P50.05) by rolipram and dexamethasone. 5 BALF nitric oxide (NO) metabolites decreased 0.5 h after ozone exposure by 52%, recovered at 2 h and signiÂźcantly increased at 12 (101%) and 24 h (127%). The elevated NO was una ected by rolipram or dexamethasone. 6 Lung oedema, measured from wet/dry weight di erences, was signiÂźcant 12, 24 and 48 h after ozone exposure, the latter being signiÂźcantly attenuated (P50.05) by rolipram and dexamethasone. 7 Ozone exposure of guinea-pigs produced features common to COPD. Although rolipram and dexamethasone did not a ect the airway function changes, they inhibited the inÂŻammation, airway hyperreactivity and oedema.